Atypical antipsychotics for insomnia: a systematic review

Area of Science:

• Pharmacology and Therapeutics
• Sleep Medicine
• Psychiatry

Background:

• Increasing use of atypical antipsychotics (e.g., quetiapine) for insomnia management.
• Concerns regarding uncertain efficacy and potential adverse effects of these medications for insomnia.

Purpose of the Study:

• To systematically evaluate the benefits and adverse effects of atypical antipsychotics when used specifically for insomnia.
• To synthesize current evidence on the efficacy and safety of these drugs in managing sleep disturbances.

Main Methods:

• Systematic review and narrative synthesis of available literature.
• Data sourced from major databases (PubMed, EMBASE, Cochrane, PsycINFO), grey literature, and pharmaceutical manufacturers.
• Inclusion of adult patients (≥18 years) using atypical antipsychotics for insomnia for at least one week, compared against active intervention or placebo.

Main Results:

• Only one double-blind randomized controlled trial (n=13) met eligibility criteria.
• Quetiapine did not show statistically significant improvements in total sleep time, sleep latency, or sleep satisfaction compared to placebo after two weeks.
• The single study was assessed as very low quality, with a trend towards improved sleep parameters but no significant differences.

Conclusions:

• Very low quality evidence indicates quetiapine does not significantly improve sleep parameters in primary insomnia.
• A trend towards clinical improvement was observed, but not statistically significant.
• Atypical antipsychotics should be avoided as first-line treatment for primary insomnia due to insufficient evidence.